linjc16/ctgov huggingface dataset:
A Consensus on Opioid Prescription for Oncologic Patients in Latin America - A DELPHI Study.

Study Overview
=================
Brief Summary
-----------------
As seen worldwide, cancer incidence is increasing in Latin America achieving an amount of 1.3 million new cases annually.1 In addition, it is expected that up to 70% of patients with cancer will experience pain2, one of the most distressing symptoms in patients with advanced cancer. And despite of advances in cancer therapies, opioids remain the mainstay treatment of cancer-related moderate-to-severe and end-of-life pain.3 However, concerns regarding opioid prescriptions have emerged for reasons like the risk of misuse and the possibility of cancer progression. In the last decades, an increase in consumption of opioids as well as in opioids-related deaths generating the so called 'opioid crisis'. This rise is mainly due to abuse / addiction of opioids. Consequently, oncologic patients are at risk for abuse, as well as for aberrant use, which can complicate the course of cancer treatment.4 5 Another feature of opioids use in cancer patients is that it may contribute to disease progression. Experimental studies suggest that opioids can may lead to immunosuppression and tumor progression or recurrence.6-8 On the other hand, retrospective analysis of clinical data shows conflicting results and trials are lacking.

Official Title
-----------------
A Consensus on Opioid Prescription for Oncologic Patients in Latin America - A DELPHI Study.

Conditions
-----------------
Cancer Patients, Cancer-related Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Head of anesthesia, Pain management and palliative care departments of cancer hospitals in Latin America. Exclusion Criteria: Surveys not answered.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survey answers | answers of the survey sent | Up to 3 (three) months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opioids, cancer-related pain, end-of-life, opioid abuse
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis

Study Overview
=================
Brief Summary
-----------------
This study investigates the variations in the retinal nerve fiber layer (RNFL) thickness during uncomplicated anterior and intermediate uveitis, respectively. The objectives are to 1 ) confirm the RNFL thickening during an uncomplicated anterior uveitis as described in the literature, 2) measure the RNFL thickness during an uncomplicated intermediate uveitis specifically and 3) describe the variation in time of RNFL thickness during the two types of uveitis.

Detailed Description
-----------------
Thirty six individuals (18 with anterior uveitis and 18 with intermediate uveitis) will be recruited at the Centre universitaire d'ophtalmologie du CHU de Québec. RNFL thickness will be measured with optical coherence tomography at 3 times. For anterior uveitis, the RNFL thickness will be measured at presentation, 1 week and 4 to 6 weeks. For intermediate uveitis, the RNFL thickness will be measured at presentation, 4 to 6 weeks and 4 months. The initial thickness will be studied for each type of uveitis and progression over time will be studied also for each type of uveitis.

Official Title
-----------------
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis

Conditions
-----------------
Anterior Uveitis, Intermediate Uveitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or more anterior uncomplicated uveitis or intermediate uncomplicated uveitis Exclusion Criteria: history of uveitis in the past, other than the actual uveitis history of ophthalmologic pathology with potential impact on retinal nerve fiber layer thickness optic nerve or macular clinically apparent edema history of glaucoma or other optic neuropathy suspected or confirmed multiple sclerosis ocular hypertension (intraocular pressure more than 22 mmHg) reduced optical coherence tomography signal (lower than 7) on the Cirrus HD-OCT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal Nerve Fiber Layer Thickness in anterior uveitis |  | At time 0 | 
| Retinal Nerve Fiber Layer Thickness in intermediate uveitis |  | At time 0 | 
| Change from Baseline Retinal Nerve Fiber Layer Thickness in anterior uveitis |  | at 4 to 6 weeks | 
| Change from Baseline Retinal Nerve Fiber Layer Thickness in intermediate uveitis |  | at 4 months |
Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Skin Prick Test Positive Control

Study Overview
=================
Brief Summary
-----------------
Skin prick test (SPT) was used for diagnostic test for type 1 hypersensitivity. The efficacy and safety of SPT were proved. The positive control of SPT is histamine. In Thailand, the most common concentration of histamine for SPT is 10 mg/ml. However, in some practice they use other concentration (1, 2.5 mg/ml). This study will find the proper concentration of histamine for positive control use in SPT.

Detailed Description
-----------------
Appropriate concentration of histamine positive control is important in interpretation the result of skin prick test.

Official Title
-----------------
Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Positive Control of Skin Prick Test

Conditions
-----------------
Immediate Hypersensitivity

Intervention / Treatment
-----------------
* Procedure: SPT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parcitipate person who attented allergy clinic, ENT clinic Legible in Thai language Exclusion Criteria: Patient cannot withhold antihistamine drug Pragnancy and lactation mother comorbid disease such as cardiac disease, liver, renal, hypertension and severe asthma

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SPT of histamine<br>SPT of histamine concentration 1, 5 and 10 mg/ml | Procedure: SPT<br>* SPT of histamine concentration 1, 5 and 10 mg/ml<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean wheal diameters of SPT of different histamine concentrations. | compare mean wheal diameters of histamine concentration 1,5, and 10 mg/ml | 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean wheal diameters of SPT of local and imported histamine positive concentration | compare mean wheal diameters of imported histamine 1 mg/ml to local histamine | 1 year |
Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

Detailed Description
-----------------
Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.

Official Title
-----------------
Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: resveratrol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months. Exclusion Criteria: Patients will be excluded from the study: Have a diagnosis of diabetes Use other antipsychotic drugs, clozapine beyond Using medicines for diabetes or dyslipidaemia Accept not participate in any stage of the research.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: resveratrol<br> | Drug: resveratrol<br>* 100mg 2x/day 1 month<br>* Other names: Placebo (10 patients);|
| Placebo Comparator: corn starch<br>(10 patients) 100mg 2x/day 1 month | Drug: resveratrol<br>* 100mg 2x/day 1 month<br>* Other names: Placebo (10 patients);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels. | Assessment of cardiovascular risk will be realized by measurement of cytokine levels (IL-12p70, IL-6, IL-10, IL-1b, IL-8 and TNF-α), C-reactive protein and cholesterol levels (total cholesterol, LDL, HDL, triglycerides) in patients with schizophrenia before and after supplementation with resveratrol or placebo. | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive performance will be assessed with a battery of cognitive tests and BPRS (brief psychiatric rating scale) to assess symptoms. | Cognitive performance will be assessed with a battery of cognitive tests (Hopkins, for verbal memory; Stroop: for executive function; Digits WAIS-III, for attention; and Sequence numbers and letters for verbal memory and attention) and BPRS (brief psychiatric rating scale) to assess symptoms. | 1 month |
Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

Study Overview
=================
Brief Summary
-----------------
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking. Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.

Official Title
-----------------
Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

Conditions
-----------------
Non-small Cell Lung Cancer Patients

Intervention / Treatment
-----------------
* Procedure: 18F-FDG-PET scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung Cancer patients with non-small cell histology and stage IV disease candidate for erlotinib treatment as first/ second/ third line of treatment Exclusion Criteria: pregnancy severe dyspnoea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18F-FDG-PET scan<br>An early evaluation 18F-FDG-PET scan after 7-10 days | Procedure: 18F-FDG-PET scan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 18F-FDG-PET evaluation | Standardized Uptake Values (SUV) will be used as measurement of 18F-FDG uptake | Time to progression and latest april 2015 (up to 2 years) |
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.

Detailed Description
-----------------
The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy.

Official Title
-----------------
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.

Conditions
-----------------
Brain Cancer, Arthritis, Rheumatoid, Central Nervous System Neoplasms, Glioma

Intervention / Treatment
-----------------
* Radiation: [18F]FHBG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Clinical diagnosis of brain tumor or rheumatoid arthritis Exclusion Criteria: - Below 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: [18F]FHBG arm<br> | Radiation: [18F]FHBG<br>* < 7mCi and 2 ug, iv<br>* Other names: 18F-FHBG;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint of the study for each patient is acquisition of PET/CT image. |  | Time of scan | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of vital signs, EKG, blood chemistry and CBC data |  | day 1, 2 and 8. |
The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience

Study Overview
=================
Brief Summary
-----------------
Background After diagnosing well-differentiated thyroid cancer (WDTC), careful assessment of the risk for disease-specific recurrence is essential for deciding between partial (low risk) and completion (high risk) thyroidectomies. Patients' preoperatively determined risk levels are re-stratified according to surgical and final histopathological findings. The American Thyroid Association 2015 guidelines suggest that patients with WDTC between 1-4 cm in size and without suspicious features may be suitable candidates for partial thyroidectomy. The incidence and clinical implications of high-risk features discovered postoperatively in patients with preoperatively determined low-risk WDTC have not been previously reported. Methods All thyroidectomies performed between 2006-2018 in the Tel Aviv Sourasky Medical Center were included. Pre- and postoperative risk stratifications were performed, and the rate of completion thyroidectomy was determined. Patients with 1-4 cm WDTC without evidence of positive cervical lymph nodes, invasion to adjacent structures, or high-risk cytology were considered at low risk for disease-specific recurrence and therefore suitable for lobectomy.

Official Title
-----------------
The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience

Conditions
-----------------
Well Differentiated Thyroid Carcinoma, Papillary Thyroid Cancer

Intervention / Treatment
-----------------
* Procedure: UNILATERAL THYROIDECTOMY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who underwent thyroid surgery (partial and total) between 2006-2018 at Tel Aviv Sourasky Medical Center (TASMC) were included Exclusion Criteria: Patients with evidence of cervical lymph node metastasis, other malignancies, adverse imaging features (i.e., extracapsular spread of thyroid malignancy, vocal cord paralysis or immobility in physical examination) were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 38 Years
Maximum Age: 61 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| UPSCALED<br> | Procedure: UNILATERAL THYROIDECTOMY<br> <br> * Other names: TOTAL THYROIDECTOMY;|
| NOT UPSCALED<br> | Procedure: UNILATERAL THYROIDECTOMY<br> <br> * Other names: TOTAL THYROIDECTOMY;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease-specific recurrence | WDTC recurrence | 2006-2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low risk, Risk stratification, Partial thyroidectomy, Hemithyroidectomy, Completion Thyroidectomy
Berlin Beat of Running Study

Study Overview
=================
Brief Summary
-----------------
This prospective observational study will investigate the frequency of new onset atrial fibrillation (AF) and of further cardiac arrhythmias as well as of (clinically silent) cerebral lesions in endurance runners before, during and after the BMW-Berlin Marathon 2011.

Detailed Description
-----------------
Up to 120 experienced marathon runners will participate in the Berlin Beat of Running Study and will wear a transportable electrocardiogram (ECG) recorder at least 24 hours before, during and 24 hours after the BMW-Berlin Marathon. All participants will undergo brain MRI examinations to detect cerebral lesions within days before and after the marathon race, respectively. Moreover, serial blood samples will be taken a few days before, immediately after as well as a few days after the BMW-Berlin Marathon.

Official Title
-----------------
Berlin Beat of Running Study - Frequency of Cardiac Arrhythmias & Cerebral Lesions in Marathon Runners

Conditions
-----------------
Cardiac Arrhythmia, Brain Lesion, Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 35-65 years at least 2 marathon runs within the last 5 years weekly running of at least 40 km Exclusion Criteria: Known cardiac arrhythmia or prior stroke contraindication for MRI.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of cardiac arrhythmias in marathon runners detected by mobile ECG-recording | During ECG recording | Up to 48 hours after the marathon race. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of (clinically silent) cerebral lesions detected by 3 Tesla brain MRI. | Up to 3 days after marathon. | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Marathon running, Brain MRI, ECG recording, Blood tests
Lifeline-NET (Narrative Exposure Therapy): A Short-term Treatment for Traumatized Refugees and Asylum Seekers

Study Overview
=================
Brief Summary
-----------------
Evaluation of a short version of Narrative Exposure Therapy

Conditions
-----------------
Trauma Treatment, Lifeline NET, Modification of Narrative Exposure Therapy

Intervention / Treatment
-----------------
* Behavioral: Lifeline NET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PTSD Exclusion Criteria: Psychotic Disorder, Severe Substance Dependence

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lifeline NET<br>Lifeline-NET (Short Version of NET) | Behavioral: Lifeline NET<br>* Short Version of Narrative Exposure Therapy<br>* Other names: LL-NET;|
| No Intervention: TAU<br>Treatment as Usual | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PTSD | Posttraumatic Stress Disorder Clinician Administered PTSD Scale | 9 months follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other Symptoms following and related to Trauma, e.g. Depression, Dissociation | Other Symptoms following and related to Trauma, e.g. Depression, Dissociation | 9 months follow up |